IL-15 trans-presentation is being explored for cancer immunotherapy; induction of constitutive expression of IL-15 and IL-15Rα by DCs or the use of soluble IL-15/IL-15Rα complexes has been shown to enhance NK cell antitumor activity in vitro and in preclinical mouse studies (reviewed in Ref. Here, IL15RA is linked to cancer.